Personalized Medicine and the Future of Health Care

Justin Xiang, PhD
Chief Investment Officer and Co-Founder
Syno Capital

Dr. Xiang is the Chief Investment Officer and Co-Founder of Syno Capital, a global healthcare and biotech investment firm based in New York City that emphasizes on cross-border collaborations between United States and China. In addition, Dr. Xiang is a senior advisor to ZhongAn Insurance, a pioneer online insurance platform in China jointly founded by Alibaba, Tencent and Ping An Insurance, as well as the Chairman and President of ZhongAn Life Sciences, a consumer healthcare subsidiary of ZhongAn Insurance. He advises ZhongAn Insurance on its healthcare strategies and oversee the integration of innovative biological sciences with its digital technology and insurance offerings through ZhongAn Life Sciences. Dr. Xiang also serves as Board Director of several venture-backed companies, including Cynvenio Biosystems, a liquid biopsy diagnostics firm in Los Angeles, CA and Orig3n, a stem cell (iPSC) technology company in Boston, MA. In the meantime, Dr. Xiang is a member of the International Advisory Council of Massachusetts General Hospital, the affiliated hospital of Harvard University.

Prior to his current roles, Dr. Xiang served as a Senior Scientist at Schrodinger Inc., a software and consulting firm backed by industry leaders including David E. Shaw and Bill Gates that specializes in computer-aided drug design. The firm's clients include global pharmaceutical companies such as Pfizer, Takeda, Roche etc. Dr. Xiang was responsible for developing next-generation computational tools for rational drug design and supporting client drug development programs. Previously, Dr. Xiang was also part of Genentech's Medicinal Chemistry team, where he participated in numerous lead drug candidate optimization programs.

Dr. Xiang holds doctoral degree in Molecular Biophysics from Washington University Medical School. His research focus was the development of cutting-edge computational models to optimize molecular modeling and drug design processes. Dr. Xiang authored several publications on this topic in internationally recognized peer-reviewed journals, including Journal of Computational Chemistry and Journal of Chemical Theory and Computation. He graduated Magna Cum Laude from Washington University in St. Louis with bachelor's degrees in Biomedical Engineering, Economics, Mathematics and Computer Science.